EntryPoint Capital LLC Acquires Shares of 7,804 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

EntryPoint Capital LLC bought a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 7,804 shares of the biopharmaceutical company’s stock, valued at approximately $256,000.

A number of other hedge funds also recently modified their holdings of AGIO. State Street Corp raised its holdings in Agios Pharmaceuticals by 10.2% in the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock valued at $103,586,000 after acquiring an additional 216,484 shares during the period. Vestal Point Capital LP acquired a new position in shares of Agios Pharmaceuticals in the third quarter valued at approximately $33,767,000. BNP Paribas Financial Markets increased its stake in shares of Agios Pharmaceuticals by 15.1% during the third quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company’s stock worth $531,000 after purchasing an additional 1,570 shares during the period. FMR LLC increased its stake in shares of Agios Pharmaceuticals by 283.2% during the third quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company’s stock worth $2,017,000 after purchasing an additional 33,546 shares during the period. Finally, Intech Investment Management LLC acquired a new stake in Agios Pharmaceuticals during the 3rd quarter worth approximately $892,000.

Analyst Ratings Changes

A number of brokerages have commented on AGIO. HC Wainwright initiated coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They issued a “buy” rating and a $58.00 price objective on the stock. Scotiabank upped their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. Royal Bank of Canada lifted their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Agios Pharmaceuticals presently has an average rating of “Hold” and an average target price of $56.57.

Insider Buying and Selling

In related news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the transaction, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. This represents a 12.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.93% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Trading Down 1.8 %

Shares of NASDAQ:AGIO opened at $30.28 on Friday. The firm has a 50 day moving average of $33.17 and a 200-day moving average of $40.87. Agios Pharmaceuticals, Inc. has a 12 month low of $27.14 and a 12 month high of $62.58. The stock has a market capitalization of $1.73 billion, a PE ratio of 2.67 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. On average, research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.